Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).

被引：0
|
作者：
Ades, Lionel
Watts, Justin M.
Radinoff, Atanas
Arnan, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua F.
Diez-Campelo, Maria
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Faller, Douglas, V
Sekeres, Mikkael A.
机构：
[1] Hop St Louis, Paris, France
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Hosp Sveti Ivan Rislki, Sofia, Bulgaria
[4] Hosp Duran & Reynals, Inst Catala Oncol, Hematol Dept, IDIBELL, Barcelona, Spain
[5] Univ Turin, Div Hematol, Turin, Italy
[6] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[8] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, CIBERONC, Salamanca, Spain
[9] Ctr Canc Res IBMCC USAL CSIC, Salamanca, Spain
[10] Catholic Univ Louvain, Ctr Hosp Univ, Namur, Yvoir, Belgium
[11] Univ Rochester, James P Wilmot Canc Inst, Rochester, NY USA
[12] AZ Sint Jan Brugge Oostende, Brugge, Belgium
[13] MHAT Dr Georgi Stranski, Clin Haematol, Pleven, Bulgaria
[14] Millennium Pharmaceut Inc, Cambridge, MA USA
[15] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7506
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
    Giagounidis, A.
    Ades, L.
    Watts, J.
    Radinoff, A.
    Arnan Sangerman, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Bell, J.
    Friedlander, S.
    Faller, D. V.
    Sekeres, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
  • [2] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
    Watts, Justin
    Ades, Lionel
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
  • [3] Pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia: a phase 2 randomized study
    Ades, Lionel
    Watts, Justin
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua F.
    Diez Campelo, Maria
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 6 - 7
  • [4] PHASE 2 STUDY OF PEVONEDISTAT plus AZACITIDINE vs AZACITIDINE IN PATIENTS WITH HIGH-RISK MYELODISPLASIC SYNDROME (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) OR ACUTE MYELOID LEUKEMIA (AML) <30% BLAST (NCT02610777)
    Diez, Campelo Maria
    Ades, Lionel
    Watts, Justin
    Radinoff, Atanas
    Arnan, Sangerman Montserrat
    Cerrano, Marco
    Font, Lopez Patricia
    Zeidner, Joshua
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    HAEMATOLOGICA, 2020, 105 : 71 - 72
  • [5] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
    Sekeres, Mikkael A.
    Fram, Robert J.
    Hua, Zhaowei
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Sekeres, Mikkael A.
    Watts, Justin
    Radinoff, Atanas
    Sangerman, Montserrat Arnan
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua F.
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Ades, Lionel
    LEUKEMIA, 2021, 35 (07) : 2119 - 2124
  • [7] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Mikkael A. Sekeres
    Justin Watts
    Atanas Radinoff
    Montserrat Arnan Sangerman
    Marco Cerrano
    Patricia Font Lopez
    Joshua F. Zeidner
    Maria Diez Campelo
    Carlos Graux
    Jane Liesveld
    Dominik Selleslag
    Nikolay Tzvetkov
    Robert J. Fram
    Dan Zhao
    Jill Bell
    Sharon Friedlander
    Douglas V. Faller
    Lionel Adès
    Leukemia, 2021, 35 : 2119 - 2124
  • [8] Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Mikkael A. Sekeres
    Justin Watts
    Atanas Radinoff
    Montserrat Arnan Sangerman
    Marco Cerrano
    Patricia Font Lopez
    Joshua F. Zeidner
    Maria Diez Campelo
    Carlos Graux
    Jane Liesveld
    Dominik Selleslag
    Nikolay Tzvetkov
    Robert J. Fram
    Dan Zhao
    Jill Bell
    Sharon Friedlander
    Douglas V. Faller
    Lionel Adès
    Leukemia, 2021, 35 : 3637 - 3637
  • [9] Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777)
    Watts, Justin
    Sekeres, Mikkael
    Radinoff, Atanas
    Arnan, Montserrat
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolai
    Fram, Robert
    Zhao, Dan
    Friedlander, Sharon
    Galinsky, Kevin
    Faller, Douglas
    Ades, Lionel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S347 - S348
  • [10] Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
    Ades, Lionel
    Girshova, Larisa
    Doronin, Vadim A.
    Diez-Campelo, Maria
    Valcarcel, David
    Kambhampati, Suman
    Viniou, Nora-Athina
    Woszczyk, Dariusz
    De Paz Arias, Raquel
    Symeonidis, Argiris
    Anagnostopoulos, Achilles
    Ciliao Munhoz, Eduardo
    Platzbecker, Uwe
    Santini, Valeria
    Fram, Robert J.
    Yuan, Ying
    Friedlander, Sharon
    Faller, Douglas, V
    Sekeres, Mikkael A.
    BLOOD ADVANCES, 2022, 6 (17) : 5132 - 5145
12345